Oivind T.
- Country
- Norway
- Department
- Nevrologisk avdeling
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Tenofovir Alafenamide and Natalizumab Combination Therapy on Epstein-Barr Virus Activity in Multiple Sclerosis Patients
- Comparative Efficacy and Safety of Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine, or Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
Data & Insights
Has run more than one trial at 113 of 284 partner sites.
Specializations
Multiple Sclerosis Treatment Expertise
This investigator specializes in advancing therapeutic approaches for multiple sclerosis (MS), with particular focus on both relapsing-remitting and progressive forms of the disease. Their research encompasses innovative treatment strategies including targeted immunotherapy and novel therapeutic agents.
- Relapsing-Remitting MS Management
- Progressive MS Treatment
- Immunological Interventions
Innovative Therapeutic Approaches
The investigator explores cutting-edge treatments including BTK inhibitors and targeted biological therapies. Their work includes evaluation of long-term safety profiles and comparative effectiveness of various therapeutic options for MS patients.
- Novel Drug Development
- Comparative Treatment Studies
- Safety Monitoring Protocols
Specialized Treatment Protocols
Research activities focus on combination therapy approaches and the development of treatment algorithms for different MS subtypes. The investigator studies add-on therapeutic strategies and their impact on disease progression.
- Treatment Optimization
- Disease Progression Management
- Therapeutic Combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.